Work

Clinical outcomes of apixaban in patients with atrial fibrillation and very high thromboembolic risk (CHA₂DS₂-VASc ≥5): a retrospective cohort study

Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background Real-world evidence on apixaban in patients with atrial fibrillation (AF) at very high thromboembolic risk (CHA₂DS₂-VASc ≥ 5) is limited, particularly from the Middle East. We compared clinical outcomes between apixaban-treated patients with CHA₂DS₂-VASc scores ≥ 5 and 0–4, and between prescribed doses within the very high-risk group. Methods In this retrospective cohort study at a tertiary referral center in Makkah, Saudi Arabia, adults with AF treated with apixaban between January 2019 and December 2024 were grouped by baseline CHA₂DS₂-VASc score. Outcomes were documented thromboembolic events, bleeding of any severity, and in-hospital mortality. Odds ratios (ORs) were estimated by unadjusted and multivariable logistic regression. A sensitivity analysis excluded patients with a recorded prior stroke. Results Of 596 patients, 175 (29.4%) had scores ≥ 5. Thromboembolic events (31.4% vs 7.1%; adjusted OR 6.6, 95% CI 3.9–11.0) and in-hospital mortality (14.3% vs 1.7%; adjusted OR 7.7, 95% CI 3.2–18.5) were more frequent with scores ≥ 5, whereas bleeding did not differ significantly (54.9% vs 46.8%; adjusted OR 1.3, 95% CI 0.9–1.9). Of 68 patients with a recorded prior stroke, 58 also had a documented thromboembolic event; after their exclusion, thromboembolic events no longer differed (5.2% vs 5.1%), whereas bleeding (adjusted OR 3.2, 95% CI 2.0–5.1) and mortality (adjusted OR 8.7, 95% CI 3.4–22.1) were more frequent with scores ≥ 5. Among very high-risk patients, prescribed dose (2.5 mg, n = 73; 5 mg, n = 102, twice daily) was not significantly associated with any outcome. Conclusions A CHA₂DS₂-VASc score ≥ 5 was associated with higher in-hospital mortality among apixaban-treated patients with AF. The excess of thromboembolic events was confined to patients with a recorded prior stroke and may reflect overlap between baseline history and outcome recording. Prescribed dose was not associated with outcomes, although dose appropriateness could not be assessed. Larger studies with complete dosing criteria and event timing are needed.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7234317462
Cites: 24
Cited by:
Related to: 10